Cargando…

Current and future therapies for type 1 diabetes

In type 1 diabetes, insulin remains the mature therapeutic cornerstone; yet, the increasing number of individuals developing type 1 diabetes (predominantly children and adolescents) still face severe complications. Fortunately, our understanding of type 1 diabetes is continuously being refined, allo...

Descripción completa

Detalles Bibliográficos
Autores principales:	von Scholten, Bernt Johan, Kreiner, Frederik F., Gough, Stephen C. L., von Herrath, Matthias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8012324/ https://www.ncbi.nlm.nih.gov/pubmed/33595677 http://dx.doi.org/10.1007/s00125-021-05398-3

Ejemplares similares

Glucagon‐like peptide‐1 receptor agonists to expand the healthy lifespan: Current and future potentials
por: Kreiner, Frederik Flindt, et al.
Publicado: (2023)

Obesity-Related Kidney Disease: Current Understanding and Future Perspectives
por: Kreiner, Frederik F., et al.
Publicado: (2023)

Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials
por: Dejgaard, Thomas F., et al.
Publicado: (2021)

Insulin at 100: still central in protein-based therapy for chronic disease
por: Kurtzhals, Peter, et al.
Publicado: (2021)

The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: from randomised trials to clinical practice
por: von Scholten, Bernt Johan, et al.
Publicado: (2022)

The potential of glucagon-like peptide-1 receptor agonists in heart failure
por: Kreiner, Frederik Flindt, et al.
Publicado: (2022)

Can We Learn From Viruses How to Prevent Type 1 Diabetes?: The Role of Viral Infections in the Pathogenesis of Type 1 Diabetes and the Development of Novel Combination Therapies
por: von Herrath, Matthias
Publicado: (2009)

Recent advances in understanding Type 1 Diabetes
por: Christoffersson, Gustaf, et al.
Publicado: (2016)

Potential viral pathogenic mechanism in human type 1 diabetes
por: Schneider, Darius A., et al.
Publicado: (2014)

The Development of Immunotherapy Strategies for the Treatment of Type 1 Diabetes
por: Coppieters, Ken, et al.
Publicado: (2018)

Urinary Alpha- and Pi-Glutathione S-Transferases in Adult Patients with Type 1 Diabetes
por: von Scholten, Bernt Johan, et al.
Publicado: (2014)

Antigen-Specific Immunotherapy for Type 1 Diabetes: Maximizing the Potential
por: Peakman, Mark, et al.
Publicado: (2010)

The Type 1 Diabetes Signature: Hardwired to Trigger Inflammation?
por: Coppieters, Ken T., et al.
Publicado: (2014)

Non-antigenic and antigenic interventions in type 1 diabetes
por: Rydén, Anna KE, et al.
Publicado: (2013)

Viral Trigger for Type 1 Diabetes: Pros and Cons
por: Filippi, Christophe M., et al.
Publicado: (2008)

Immunotherapy for the Prevention and Treatment of Type 1 Diabetes: Optimizing the path from bench to bedside
por: Bresson, Damien, et al.
Publicado: (2009)

A Deeper Look into Type 1 Diabetes – Imaging Immune Responses during Onset of Disease
por: Christoffersson, Gustaf, et al.
Publicado: (2016)

Cure of Chronic Viral Infection and Virus-Induced Type 1 Diabetes by Neutralizing Antibodies
por: Ejrnaes, Mette, et al.
Publicado: (2006)

Cure of Chronic Viral Infection and Virus-Induced Type 1 Diabetes by Neutralizing Antibodies
por: Ejrnaes, Mette, et al.
Publicado: (2006)

Metabolic syndrome – Removing roadblocks to therapy: Antigenic immunotherapies()
por: Coppieters, Ken T., et al.
Publicado: (2014)

The importance of addressing multiple risk markers in type 2 diabetes: Results from the LEADER and SUSTAIN 6 trials
por: Zobel, Emilie H., et al.
Publicado: (2021)

New Insights Into the Role of Autoreactive CD8 T Cells and Cytokines in Human Type 1 Diabetes
por: Bender, Christine, et al.
Publicado: (2021)

Epicardial adipose tissue: an emerging biomarker of cardiovascular complications in type 2 diabetes?
por: Christensen, Regitse Højgaard, et al.
Publicado: (2020)

Antigen-Specific Regulatory T Cells and Low Dose of IL-2 in Treatment of Type 1 Diabetes
por: Pham, Minh N., et al.
Publicado: (2016)

Therapies for Type 1 Diabetes: Current Scenario and Future Perspectives
por: Pathak, Varun, et al.
Publicado: (2019)

Pleiotropic effects of liraglutide in patients with type 2 diabetes and moderate renal impairment: Individual effects of treatment
por: Zobel, Emilie H., et al.
Publicado: (2019)

Editorial: Advanced Cardiovascular Imaging in Diabetes
por: Schick, Fritz, et al.
Publicado: (2022)

Response to Comment on Rodriguez-Calvo et al. Increase in Pancreatic Proinsulin and Preservation of β-Cell Mass in Autoantibody-Positive Donors Prior to Type 1 Diabetes Onset. Diabetes 2017;66:1334–1345
por: Rodriguez-Calvo, Teresa, et al.
Publicado: (2017)

Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial
por: Persson, Frederik, et al.
Publicado: (2021)

Temporal Intra-Individual Variation of Immunological Biomarkers in Type 1 Diabetes Patients: Implications for Future Use in Cross-Sectional Assessment
por: Sarikonda, Ghanashyam, et al.
Publicado: (2013)

T-bet Controls Autoaggressive CD8 Lymphocyte Responses in Type 1 Diabetes
por: Juedes, Amy E., et al.
Publicado: (2004)

Growth differentiation factor-15 and fibroblast growth factor-23 are associated with mortality in type 2 diabetes – An observational follow-up study
por: Frimodt-Møller, Marie, et al.
Publicado: (2018)

Epicardial adipose tissue predicts incident cardiovascular disease and mortality in patients with type 2 diabetes
por: Christensen, Regitse H., et al.
Publicado: (2019)

The healthy exocrine pancreas contains preproinsulin-specific CD8 T cells that attack islets in type 1 diabetes
por: Bender, Christine, et al.
Publicado: (2020)

Increased Immune Cell Infiltration of the Exocrine Pancreas: A Possible Contribution to the Pathogenesis of Type 1 Diabetes
por: Rodriguez-Calvo, Teresa, et al.
Publicado: (2014)

Symmetric and asymmetric dimethylarginine as risk markers of cardiovascular disease, all-cause mortality and deterioration in kidney function in persons with type 2 diabetes and microalbuminuria
por: Zobel, Emilie H., et al.
Publicado: (2017)

Erratum. Increased Immune Cell Infiltration of the Exocrine Pancreas: A Possible Contribution to the Pathogenesis of Type 1 Diabetes. Diabetes 2014;63:3880–3890
por: Rodriguez-Calvo, Teresa, et al.
Publicado: (2016)

Impaired coronary microcirculation in type 2 diabetic patients is associated with elevated circulating regulatory T cells and reduced number of IL-21R(+) T cells
por: von Scholten, Bernt Johan, et al.
Publicado: (2016)

Lost in translation: barriers to implementing clinical immunotherapeutics for autoimmunity
por: von Herrath, Matthias G., et al.
Publicado: (2005)

Effect of large weight reductions on measured and estimated kidney function
por: von Scholten, Bernt Johan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_609bmieu8qtaaevjp9eb2p5ica